Skip to main content
S 2543 116th Congress Senate Health Accounting and auditing Administrative law and regulatory procedures Appropriations Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Fraud offenses and financial crimes Genetics Government information and archives Government studies and investigations Health care costs and insurance Health care coverage and access Health care quality Health technology, devices, supplies Home and outpatient care Hospital care Indian social and development programs Inflation and prices

Prescription Drug Pricing Reduction Act of 2019

Introduced: September 25, 2019 Introduced by: Grassley, Chuck Republican · Iowa See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Sep 25, 2019
Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.
Sep 25, 2019
Committee on Finance. Original measure reported to Senate by Senator Grassley. With written report No. 116-120.
Sep 25, 2019
Introduced in Senate
 Plain-English summary Congressional Research Service

Prescription Drug Pricing Reduction Act of 2019

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

  • requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
  • requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
  • reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
  • requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
  • requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
  • increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.
What's happening now September 25, 2019

Placed on Senate Legislative Calendar under General Orders. Calendar No. 225.

 Committees of jurisdiction 1